dactinomycin has been researched along with abt-737 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krystal, GW; Xu, H | 1 |
| Li, C; Olberding, KE; Pan, J; Rai, SN; Wang, X; Zhu, Y | 1 |
| Krystal, GW | 1 |
| Akagi, J; Darzynkiewicz, Z; Dobrucki, J; Errington, R; Kordon, M; Matuszek, A; Smith, PJ; Takeda, K; Wlodkowic, D; Zhao, H | 1 |
| Calvello, R; Cianciulli, A; Panaro, MA; Porro, C; Trotta, T | 1 |
5 other study(ies) available for dactinomycin and abt-737
| Article | Year |
|---|---|
Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
Topics: Antibiotics, Antineoplastic; Apoptosis; Biphenyl Compounds; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; G2 Phase; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Small Cell Lung Carcinoma; Sulfonamides; Time Factors | 2010 |
Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dactinomycin; Down-Regulation; Drug Synergism; Gene Expression; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Pancreatic Neoplasms; Peptide Fragments; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Sulfonamides | 2010 |
Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Biphenyl Compounds; Dactinomycin; Drug Synergism; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Peptide Fragments; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2010 |
Real-time cell viability assays using a new anthracycline derivative DRAQ7®.
Topics: Anthracyclines; Apoptosis; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Dactinomycin; DNA Damage; Etoposide; Flow Cytometry; Fluorescent Dyes; Histones; Humans; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Nitrophenols; Piperazines; Rhodamines; Staurosporine; Sulfonamides; Sulfones | 2013 |
Resistance to apoptosis in Leishmania infantum-infected human macrophages: a critical role for anti-apoptotic Bcl-2 protein and cellular IAP1/2.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Biphenyl Compounds; Cell Line; Dactinomycin; Disease Resistance; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Leishmania infantum; Macrophages; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Ubiquitin-Protein Ligases | 2018 |